--- schema_version: "secwatch.filing_event.v1" accession: "0000875320-23-000015" form_type: "8-K" ticker: "VRTX" cik: "0000875320" company_name: "VERTEX PHARMACEUTICALS INC / MA" filed_at: "2023-05-18T23:59:59+00:00" generated_at: "2026-06-14T21:54:51.681647+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.1 calibrated_materiality_score: 0.1 confidence: "high" source: SEC EDGAR --- # Vertex shareholders elect all nine director nominees at 2023 annual meeting ## Summary - All nine director nominees elected; votes ranged from 203.8M to 223.0M in favor. - Ernst & Young ratified as independent auditor for 2023: 226.5M for, 7.8M against. - Advisory approval of 2022 executive compensation passed with 200.9M for (~89% of votes cast). - Shareholders recommended annual frequency for future advisory votes (222.8M for 1 year); board adopts annual schedule. - Non-votes on director election, compensation, and frequency proposals were 9.8M shares (broker non-votes). ## SEC filing metadata - accession: 0000875320-23-000015 - form_type: 8-K - ticker: VRTX - cik: 0000875320 - company_name: VERTEX PHARMACEUTICALS INC / MA - filed_at: 2023-05-18T23:59:59+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.1 - calibrated_materiality_score: 0.1 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/0000875320-23-000015-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/vrtx-20230517.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000875320-23-000015 - JSON: https://secwatch.observer/filing/0000875320-23-000015.json - Plain text: https://secwatch.observer/filing/0000875320-23-000015.txt ## Key facts - Shareholder Votes VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-05-17 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-05-17 source text: Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023: For Against Abstain Non-Votes 226,512,223 7,826,181 151,725 0 evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/0000875320-23-000015-index.htm - Shareholder Votes VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-17 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2023-05-17 source text: Proposal No. 4: Based upon the following votes, the shareholders recommended, on an advisory basis, to hold future advisory votes to approve executive compensation on an annual basis: 1 Year 2 Years 3 Years Abstain Non-Votes 222,845,689 100,872 1,607,838 109,401 9,826,329 evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/0000875320-23-000015-index.htm - Shareholder Votes VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of the nine nominees to serve as directors at the 2023-05-17 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-05-17 source text: Proposal No. 1 : Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Jeffrey Leiden, Diana McKenzie, Bruce Sachs and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2024: For Against Abstain Non-Votes Sangeeta Bhatia 222,080,665 2,466,298 116,837 9,826,329 Lloyd Carney 209,020,156 15,522,060 121,584 9,826,329 Alan Garber 222,238,564 2,300,900 124,336 9,826,329 Terrence Kearney 212,386,123 12,155,694 121,983 9,826,329 Reshma Kewalramani 222,944,919 1,605,123 113,758 9,826,329 Jeffrey Leiden 216,063,881 7,824,259 775,660 9,826,329 Diana McKenzie 222,081,247 2,466,571 115,982 9,826,329 Bruce Sachs 203,818,027 20,714,176 131,597 9,826,329 Suketu Upadhyay 222,991,778 1,551,263 120,759 9,826,329 evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/0000875320-23-000015-index.htm - Shareholder Votes VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2022 compensation program for named executive officers at the 2023-05-17 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-05-17 source text: Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2022 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 200,867,116 23,641,105 155,579 9,826,329 evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000015/0000875320-23-000015-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.